Pulmonary drug delivery via nanoparticles has shown great potential in treating patients who are highly pretreated for chronic conditions like asthma, chronic obstructive pulmonary disease (COPD), or lung cancer. Nanoparticles can be a perfect way to deliver therapeutic drugs that demonstrate suppressed solubility in pulmonary blood secretions. In regular oral administration, multiple droplets of drug are free from drug and others are densely filled with the drug at high concentrations, directing to good circulation and distribution of the drug throughout the body. But when the drug is released into the pulmonary circulation, solute concentrations drop drastically as a result of water droplets clogging the air ways.
Market Dynamics
Increasing prevalence of asthma is expected to propel growth of the global pulmonary drug delivery systems market. For instance, according to The Global Asthma Report 2018, around 300 million people have asthma worldwide, and the number is expected to reach 100 million by 2025.
Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the global pulmonary drug delivery systems market. For instance, globally, as of 9:39am CET, 22 December 2020, there have been 76,023,488 confirmed cases of COVID-19, including 1,694,128 deaths, reported to the World Health Organization.
Moreover, increasing number of clinical trials for development of new drugs is also expected to aid in growth of the market. For instance, in December 2020, TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced dosing of the first subjects in its Phase 1b clinical trial of Voriconazole Inhalation Powder, a next-generation, direct-to-lung, inhaled dry powder version of voriconazole, which is generally considered to be the most effective antifungal drug for treatment of Aspergillosis infections.
Competitive Analysis
Major players operating in the global pulmonary drug delivery systems market include, 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca plc, Boehringer Ingelheim, CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., Philips Healthcare, and Liquidia Technologies, Inc.
Major players operating in the global pulmonary drug delivery systems market are focused on approval and launch of new products to expand their product portfolio. For instance, in November 2020, Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation, announced that the U.S. Food and Drug Administration has issued a complete response letter for the company’s New Drug Application for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension.
In-depth Report on Pulmonary Drug Delivery Systems Market by Coherent Market Insights:
https://www.coherentmarketinsights.com/market-insight/pulmonary-drug-delivery-systems-market-3952
No comments:
Post a Comment